Abstract
Nephrogenic syndrome of inappropriate antidiuresis (NSIAD), first described in 2005, is a rare genetic X-linked disease, presenting with hyponatremia, hyposmolarity, euvolemia, inappropriately concentrated urine, increased natriuresis, and undetectable or very low arginine-vasopressine (AVP) circulating levels. It can occur in neonates, infants, or later in life. NSIAD must be early recognized and treated to prevent severe hyponatremia, which can show a dangerous impact on neonatal outcome. In fact, it potentially leads to death or, in case of survival, neurologic sequelae. This review is an update of NSIAD 12 years after the first description, focusing on reported cases of neonatal and infantile onset. The different molecular patterns affecting the AVP receptor 2 (V2R) and determining its gain of function are reported in detail; moreover, we also provide a comparison between the different triggers involved in the development of hyponatremia, the evolution of the symptoms, and modality and efficacy of the different treatments available.
Similar content being viewed by others
References
Levtchenko EN, Monnens LAH (2010) Nephrogenic syndrome of inappropriate antidiuresis. Nephrol Dial Transplant 25:2839–2843
Powlson AS, Challis BG, Halsall DJ, Schoenmakers E, Gurnell M (2016) Nephrogenic syndrome of inappropriate antidiuresis secondary to an activating mutation in the arginine vasopressin receptor AVPR2. Clin Endocr 85:306–312
Marcialis MA, Faa V, Fanos V, Puddu M, Pintus MC, Cao A, Rosatelli MC (2008) Neonatal onset of nephrogenic syndrome of inappropriate antidiuresis. Pediatr Nephrol 23:2267–2271
Tiulpakov A, White CW, Abhayawardana RS, See HB, Chan AS, Seeber RM, Heng JI, Dedov I, Pavlos NJ, Pfleger KD (2016) Mutations of vasopressin receptor 2 including novel L312S have differential effects on trafficking. Mol Endocrinol 30:889–904
Carpentier E, Greenbaum LA, Rochdi D, Abrol R, Goddard WA, Bichet DG, Bouvier M (2012) Identification and characterization of an activating F 229V substitution in the V2 vasopressin receptor in an infant with NSIAD. J Am Soc Nephrol 23:1635–1640
Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE (2005) Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 352:1884–1890
Ranchin B, Boury-Jamot M, Blanchard G, Dubourg L, Hadj-Aïssa A, Morin D, Durroux T, Cochat P, Bricca G, Verbavatz JM, Geelen G (2010) Familial nephrogenic syndrome of inappropriate antidiuresis: dissociation between aquaporin-2 and vasopressin excretion. J Clin Endocrinol Metab 95(9):E37–E43
Gupta S, Cheetham TD, Lambert HJ, Roberts C, Bourn D, Coulthard MG, Ball SG (2009) Thirst perception and arginine-vasopressin production in a kindred with an activating mutation of the type 2 vasopressin receptor: the pathophysiology of nephrogenic syndrome of inappropriate antidiuresis. Eur J Endocrinol 161:503–508
Bes DF, Mendilaharzu H, Fenwick RG, Arrizurieta E (2007) Hyponatremia resulting from arginine vasopressin receptor 2 gene mutation. Pediatr Nephrol 22:463–466
Decaux G, Vandergheynst F, Bouko Y, Parma J, Vassart G, Vilain C (2007) Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotype variability in men and women from a large pedigree. J Am Soc Nephrol 18:606–612
Bockenhauer D, Penney MD, Hampton D, van’t Hoff W, Gullett A, Sailesh S, Bichet DG (2012) A family with hyponatremia and the nephrogenic syndrome of inappropriate antidiuresis. Am J Kidney Dis 59:566–568
Cailleaux A, Mahieu F, Heinrichs C, Adams B, Ismaili K, Brachet C (2017) Nephrogenic syndrome of inappropriate antidiuresis: early diagnosis avoids severe hyponatremia complications. Arch Pediatr 24:630–663
Morin D, Tenenbaum J, Ranchin B, Durroux T (2012) Nephrogenic syndrome of inappropriate antidiuresis. Int J Ped 2012:937175
Cheung CC, Cadnapaphomchai MA, Ranadive SA, Gitelman SE, Rosenthal SM (2012) Persistent elevation of urine aquaporin-2 during water loading in a child with nephrogenic syndrome of inappropriate antidiuresis (NSIAD) caused by a R137L mutation in the V2 vasopressin receptor. Int J of Ped Endocrinol 2012:3
Robertson GL (2006) Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med 119:S36–S42
Adrogué H, Madias N (2000) Hyponatremia. N Engl J Med 342:1581–1589
Halberthal M, Halperin M, Bohn D (2001) Acute hyponatremia in children admitted to hospital: retrospective analysis of factors contributing to its development and resolution. BMJ 322:780–782
Adelman R, Solhaug M (2000) Pathophysiology of body fluids and fluid therapy. In: Behrman, Kliegman, Jenson, eds. Nelson textbook of pediatrics, 16th ed. Philadelphia: WB Saunders, 202
Palmer B, Gates J, Lader M (2003) Causes and management of hyponatremia. Ann Pharmacother 37:1694–1702
Cho YH, Gitelman S, Rosenthal S, Ambler G (2009) Long-term outcomes in a family with nephrogenic syndrome of inappropriate antidiuresis. Int J Pediatr Endocrinol 2009:431527
Vandergheynst F, Brachet C, Heinrichs C, Decaux G (2012) Long-term treatment of hyponatremic patients with nephrogenic syndrome of inappropriate antidiuresis: personal experience and review of published case reports. Nephron Clin Pract 120:168–172
Brachet C, Vandergheynst F, Heinrichs C (2015) Nephrogenic syndrome of inappropriate antidiuresis in a female: review of the clinical presentation in females. Horm Res Paediatr 84:65–67
Ball SG (2007) Vasopressin and disorders of water balance: the physiology and pathophysiology of vasopressin. Ann Clin Biochem 44:417–431
Morello JP, Bichet DG (2001) Nephrogenic diabetes insipidus. Annu Rev Physiol 63:607–630
Barberis C, Mouillac B, Durroux T (1998) Structural bases of vasopressin/oxytocin receptor function. J Endocrinol 156:223–229
Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W (1992) Molecular cloning of the receptor for human antidiuretic hormone. Nature 357:333–335
Seibold A, Brabet P, Rosenthal W, Birnbaumer M (1992) Structure and chromosomal localization of the human antidiuretic hormone receptor gene. Am J Hum Genet 51:1078–1083
Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG (1999) Association of β-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J BiolChem 274:32248–32257
Knoers NV, van den Ouweland AM, Verdijk M, Monnens LA, van Oost BA (1994) Inheritance of mutations in the V2 receptor gene in thirteen families with nephrogenic diabetes insipidus. Kidney Int 46:170–176
Bockenhauer D, Carpentier E, Rochdi D, van’t Hoff W, Breton B, Bernier V, Bouvier M, Bichet DG (2010) Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus. Nephron Physiol 114:1–10
Lia-Baldini AS, Magdelaine C, Nizou A, Airault C, Salles JP, Moulin P, Delemer B, Aitouares M, Funalot B, Sturtz F, Lienhardt-Roussie A (2013) Two novel mutations of the calcium-sensing receptor gene affecting the same amino acid position lead to opposite phenotypes and reveal the importance of p.N802 on receptor activity. Eur J Endocrinol 168:27–34
Rovati GE, Capra V, Neubig RR (2007) The highly conserved DRY motif of class AG protein-coupled receptors: beyond the ground state. Mol Pharmacol 71:959–964
Audet M, Bouvier M (2012) Restructuring G-protein-coupled receptor activation. Cell 151:14–23
Tenenbaum J, Ayoub MA, Perkovska S, Adra-Delenne AL, Mendre C, Ranchin B, Bricca G, Geelen G, Mouillac B, Durroux T, Morin D (2009) The constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation. PLoS One 4:8383
Rochdi MD, Vargas GA, Carpentier E, Oligny-Longprè G, Chen S, Kovoor A, Gitelman SE, Rosenthal SM, von Zastrow M, Bouvier M (2010) Functional characterization of V2-vasopressin receptor substitutions (R137 H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol Pharmacol 77:836–845
Erdélyi LS, Mann WA, Morris-Rosendahl HL, Groβ U, Nagel M, Vàrnai P, Balla A, Hunyady L (2015) Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis. Kidney Int 88:1070–1078
Kocan M, See HB, Sampaio NG, Eidne KA, Feldman BJ, Pfleger KD (2009) Agonist-independent interactions between β-arrestins and mutants vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis. Mol Endocrinol 23:559–571
Kocan M, Dalrymple MB, Seeber RM, Feldman BJ, Pfleger KD (2011) Enhanced BRET technology for the monitoring of agonist-induced and agonist-independent interactions between GPCRs and β-arrestins. Front Endocrinol 1:12
Gitelman SE, Feldman BJ, Rosenthal SM (2006) Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients. Am J Med 119:554–558
Huang EA, Feldman BJ, Schwartz ID, Geller DH, Rosenthal SM, Gitelman SE (2006) Oral urea for the treatment of chronic syndrome of inappropriate antidiuresis in children. J Pediatr 148:128–134
Sterns RH, Silver SM, Hix JK (2015) Urea for hyponatremia? Kidney Int 87:268–270
Dufek S, Booth C, Carrol A, van’t Hoff W, Kleta R, Bockenhauer D (2017) Urea is successful in treating inappropriate antidiuretic hormone secretion in an infant. https://doi.org/10.1111/apa.13697
Decaux G, Soupart A (2003) Treatment of symptomatic hyponatremia. Am J Med Sci 326:25–30
Decaux G, Andres C, Gankam Kengne F, Soupart A (2010) Treatment of euvolemic hyponatremia in the intensive unit care by urea. Crit Care 14:R184
Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichsi C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E, Hyponatremia guideline development group (2014) Clinical practice guideline on diagnosis and treatment of hyponatremia. Nephrol Dial Transplant 29(Suppl2):i1–i39
Soupart A, Coffernils M, Couturier B, Gankam-Kengne F, Decaux G (2012) Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol 7:742–747
Gankam Kengne F, Couturier BS, Soupart A, Decaux G (2015) Urea minimizes brain complications following rapid correction of chronic hyponatremia compared with vasopressin antagonist or hypertonic saline. Kidney Int 87:323–331
Moreno Montero A, Barcelό Caňellas C, Brigante Ucedo JI, Garcia Baglietto A, Marhuenda Irastorza C (2014) One-step low profile percutaneous endoscopic gastrostomy: our experience in children. Cir Pediatr 27(4):196–200
Göthberg G, Björnsson S (2016) One-step insertion of low-profile gastrostomy in pediatric patients vs pull percutaneous endoscopic gastrostomy: retrospective analysis of outcomes. J Parent Enteral Nutr 40(3):423–430
Lerich LW, Ortiz-Melo DI, Patel MB, Greenberg A (2013) Role of vaptans in the management of hyponatremia. Am J Kidney Dis 62(2):364–376
Peri A (2013) The use of vaptans in clinical endocrinology. J Clin Endocrinol Metab 98:1321–1332
Bichet DG (2012) What is the role of vaptans in routine clinical nephrology? Clin J Am Soc Nephrol 7:700–703
Marx-Berger D, Milford DV, Bandhakavi M, Van’t Holf W, Kleta R, Dattani M, Bockenhauer D (2016) Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants. Acta Paed 105:334–337
Higashi K, Murakami T, Ishikawa Y, Itoi T, Ohuchi H, Kodama Y, Honda T, Masutani S, Yamasawa H, Senzaki H, Ishikawa S (2016) Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of Pediatric Circulation and Hemodynamics. Int J Cardiol 205:37–42
Regen RB, Gonzalez A, Zawodniak K, Leonard D, Quigley R, Barnes AP, Koch JD (2013) Tolvaptan increases serum sodium in pediatric patients with heart failure. Pediatr Cardiol 34:1463–1468
Horibata Y, Murakami T, Niwa K (2014) Effect of the oral vasopressin receptor antagonist tolvaptan on congestive cardiac failure in a child with restrictive cardiomyopathy. Cardiol Youn 24:155–157
Shimizu M, Ishikawa S, Yachi Y, Muraoka M, Tasaki Y, Iwasaki H, Kuroda M, Ohta K, Yachie A (2014) Tolvaptan therapy for massive edema in a patient with nephritic syndrome. Pediatr Nephrol 29:915–917
Rianthavorn P, Cain JP, Turman MA (2008) Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and DIADH. Pediatr Nephrol 23:1367–1370
Kraayvanger I, Latza J, Vackelmann C, Berlit P, Weber R (2014) Tolvaptan treatment of severe stroke-like symptoms and bilateral subcortical diffusion restriction due to syndrome of inappropriate secretion of ADH after polytrauma. J Neurol 261:1436–1438
Willemsen RH, Delgado-Carballar V, Elleri D, Thankamony A, Burke GA, Nicholson JC, Dunger DB (2016) Tolvaptan use during hyperhydration in paediatric intracranial lymphoma with SIADH. Endocrinol Diabetes 16:0066
Tuli G, Tessaris D, Einaudi S, De Sanctis L, Matarazzo P (2017) Tolvaptan treatment in children with chronic hyponatremia due to inappropriate antidiuretic hormone secretion: a report of three cases. J Clin Res Pediatr Endocrinol 9:288–292
Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA (2015) Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trial database. Drug Saf 38:1103–1113
Hasler U (2009) Controlled aquaporin-2 expression in the hypertonic environment. Am J Physiol Cell Physiol 296:C641–C653
Acknowledgements
We sincerely thank Professor Stephen E. Gitelman, Professor of Pediatrics Chief, Division of Pediatric Endocrinology and Diabetes, University of California at San Francisco, for his availability and speed in clarifying some information about the two patients affected by NSIAD described in the paper published with his research group in 2005.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Rights and permissions
About this article
Cite this article
Bardanzellu, F., Pintus, M.C., Masile, V. et al. Focus on neonatal and infantile onset of nephrogenic syndrome of inappropriate antidiuresis: 12 years later. Pediatr Nephrol 34, 763–775 (2019). https://doi.org/10.1007/s00467-018-3922-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-018-3922-6